ESTRO 2023 - Abstract Book

S1211

Digital Posters

ESTRO 2023

Conclusion Elderly patients show optimal biochemical control and safe GI/GU toxicity profiles. In conclusion, in this setting of patients, with the aim to propose a curative treatment and, at the same time, to preserve the quality of life in these frail patients, personalized ultra UHRT +/- short ADT course should be considered as a treatment option, according to oncological characteristics and comorbidities.

PO-1493 Health-related quality of life in extreme hypofractionation for localized prostate cancer

I. Bonavero 1 , G.C. Iorio 1 , G. Petruzzellis 1 , D. Bongiovanni 1 , S. Bartoncini 1 , E. Gallio 2 , V. Chiofalo 1 , E.M. Cuffini 1 , C. Grossi 1 , M. Levis 1 , U. Ricardi 1 1 University of Turin, Department of Oncology, Turin, Italy; 2 University of Turin, Department of Medical Physics, Turin, Italy Purpose or Objective Extreme hypofractionation is gradually becoming a mainstay of treatment for prostate cancer (PCa). Patients’ (pts) tolerance to such RT regimes is certainly under the spotlight. Herein, we report health-related quality of life (HRQOL) data in a single-center observational study. Materials and Methods In this observational study of a consecutive series of low- to high-risk PCa pts treated with (LINAC-based VMAT) extreme hypofractionation (42.7 Gy/7 fractions) +/- ADT, HRQOL up to 1 year from treatment was evaluated through the italian short-form of the UCLA-Prostate Cancer Index (-PCI). This short-form is a self-administered 14-item questionnaire that quantifies prostate-specific HRQOL in six domains, urinary function (UF) and bother (UB), bowel function (BF) and bother (BB), and sexual function (SF) and bother (SB). The scales are scored from 0 to 100, with higher scores representing better health states. The questionnaire was administered at baseline, RT end, 1-month (mo), 3-mos, 6-mos and 12-mos from the end of RT. Moreover, IPSS scores and RTOG toxicity were simultaneously recorded to address a complete tolerance evaluation. Results 117 pts (mean age 74 years) were treated between May 2020 and September 2021. At RT end 70% of pts were undergoing ADT, 53% at 3-mos, 28% at 6-mos, only 24% at 1-year. An IPSS score >12 at the baseline was reported for the 21.4% of the population. UF did not significantly change along the timepoints, with mean scores ranging from 89 at baseline to 86 at 1 year (Fig. 1). UB dropped significantly at RT end (mean score 62 vs 76 at baseline), and gradually improved with equivalent/slightly higher scores than baseline from 3-mos to 1-year (Fig. 2). This in line with: RTOG GU G2+ toxicity, which peaked at RT end (20.5%) and gradually decreased at 3-mos (0%) with negligible rates at 1-year (3.4%); and with mean IPSS scores, that peaked at RT end (13 vs 8.4 baseline) and gradually decreased at 3-mos (8.6) and 1-year (7.7). BF dropped at RT end (mean score 77 vs 86 at baseline), and gradually improved with equivalent/slightly higher scores than baseline from 3-mos to 1-year (Fig. 1). BB dropped at 1-mo (mean score 70 vs 79 at baseline), and gradually improved with equivalent/slightly higher scores than baseline from 3-mos to 1-year (Fig. 2). In this regard, RTOG GI G2+ rates were overall negligible: 1.7% at RT end, and 0.8% at 3-mos and 1-year.SF and SB (Fig. 1-2) gradually decreased along the timepoints, with the mean lowest scores recorded at 1-year: 24 for SF (vs 40 at baseline) and 35 for SB (vs 53 at baseline).